LDL cholesterol-lowering therapies: Emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors

F. Sabatel-Pérez, A. García-Ropero, C. G. Santos-Gallego, M. Urooj Zafar, J. J. Badimón

Research output: Contribution to journalArticlepeer-review

Abstract

Atherosclerotic cardiovascular disease is the leading cause of death all over the world. Its etiopathogenesis involves many correlated processes, with hypercholesterolemia being one of the main risk factors. Several large clinical trials have established the association between low-density lipoprotein cholesterol (LDL-C) levels and cardiovascular events. With the aim to take control over high LDL-C levels, several drugs with different targets in the cholesterol pathway have been developed. Statins are the cornerstone of pharmacological lipid-lowering treatment, although they are not always successful in attaining the recommended LDL-C levels. Therefore, newer and more potent therapies have been developed, being prominent among them ezetimibe and especially the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Recent trials with these new therapies have reaffirmed the theory of 'the lower, the better' when it comes to LDL-C levels, and 'the earlier, the better' when it comes to atherosclerotic physiopathology.

Original languageEnglish
Pages (from-to)329-344
Number of pages16
JournalDrugs of Today
Volume55
Issue number5
DOIs
StatePublished - May 2019

Keywords

  • Hypercholesterolemia
  • LDL cholesterol
  • Lipoprotein disorders
  • Metabolic diseases
  • PCSK9 inhibitors
  • Statins

Fingerprint

Dive into the research topics of 'LDL cholesterol-lowering therapies: Emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors'. Together they form a unique fingerprint.

Cite this